drugset / Trial / NCT03482011
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2018-04-24
- Primary completion
- 2019-03-21
- Completion
- 2020-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 125 mg | Subcutaneous |
| Subject | Mirikizumab | Monoclonal antibody | 250 mg | Subcutaneous |